Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of SENJU PHARMACEUTICAL CO LTD.

    Client Virtual Booth

    SENJU PHARMACEUTICAL CO LTD

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    SENJU PHARMACEUTICAL CO LTD
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    2-5-8,Hirano-machi, Chuo-ku, Osaka
    Telephone
    Telephone
    +81 06 201 2512
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.senju.co.jp/english/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Senju Pharmaceutical and Novaliq Enter into License Agreement for NOV03 (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of Dry Eye Disease ...

    Details:

    Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Product Name: NOV'03

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Novaliq

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement June 13, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Senju Pharmaceutical Launches New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension

    Details:

    New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.


    Lead Product(s): Brimonidine Tartrate,Brinzolamide

    Therapeutic Area: Ophthalmology Product Name: Ailamide

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 16, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search